Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents
The number of treatment options for acute myeloid leukemia (AML) has greatly increased since 2017. This development is paralleled by the broad implantation of genetic profiling as an integral part of clinical studies, enabling us to characterize mutation–response, mutation–non-response, or mutation–...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/7/1689 |
_version_ | 1797440107977900032 |
---|---|
author | Adriane Halik Christopher Maximilian Arends Lars Bullinger Frederik Damm Mareike Frick |
author_facet | Adriane Halik Christopher Maximilian Arends Lars Bullinger Frederik Damm Mareike Frick |
author_sort | Adriane Halik |
collection | DOAJ |
description | The number of treatment options for acute myeloid leukemia (AML) has greatly increased since 2017. This development is paralleled by the broad implantation of genetic profiling as an integral part of clinical studies, enabling us to characterize mutation–response, mutation–non-response, or mutation–relapse patterns. The aim of this review is to provide a concise overview of the current state of knowledge with respect to newly approved AML treatment options and the association of response, relapse and resistance with genetic alterations. Specifically, we will highlight current genetic data regarding FLT3 inhibitors, IDH inhibitors, hypomethylating agents (HMA), the BCL-2 inhibitor venetoclax (VEN), the anti-CD33 antibody conjugate gemtuzumab ozogamicin (GO) and the liposomal dual drug CPX-351. |
first_indexed | 2024-03-09T12:03:22Z |
format | Article |
id | doaj.art-10905d6c19f64d9582a4f9673b554ff3 |
institution | Directory Open Access Journal |
issn | 2072-6694 |
language | English |
last_indexed | 2024-03-09T12:03:22Z |
publishDate | 2022-03-01 |
publisher | MDPI AG |
record_format | Article |
series | Cancers |
spelling | doaj.art-10905d6c19f64d9582a4f9673b554ff32023-11-30T23:00:38ZengMDPI AGCancers2072-66942022-03-01147168910.3390/cancers14071689Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New AgentsAdriane Halik0Christopher Maximilian Arends1Lars Bullinger2Frederik Damm3Mareike Frick4Medical Department, Division of Hematology, Oncology, and Cancer Immunology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, GermanyMedical Department, Division of Hematology, Oncology, and Cancer Immunology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, GermanyMedical Department, Division of Hematology, Oncology, and Cancer Immunology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, GermanyMedical Department, Division of Hematology, Oncology, and Cancer Immunology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, GermanyMedical Department, Division of Hematology, Oncology, and Cancer Immunology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, GermanyThe number of treatment options for acute myeloid leukemia (AML) has greatly increased since 2017. This development is paralleled by the broad implantation of genetic profiling as an integral part of clinical studies, enabling us to characterize mutation–response, mutation–non-response, or mutation–relapse patterns. The aim of this review is to provide a concise overview of the current state of knowledge with respect to newly approved AML treatment options and the association of response, relapse and resistance with genetic alterations. Specifically, we will highlight current genetic data regarding FLT3 inhibitors, IDH inhibitors, hypomethylating agents (HMA), the BCL-2 inhibitor venetoclax (VEN), the anti-CD33 antibody conjugate gemtuzumab ozogamicin (GO) and the liposomal dual drug CPX-351.https://www.mdpi.com/2072-6694/14/7/1689AMLmutationsFLT3IDH1/2venetoclaxgemtuzumabozogamicin |
spellingShingle | Adriane Halik Christopher Maximilian Arends Lars Bullinger Frederik Damm Mareike Frick Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents Cancers AML mutations FLT3 IDH1/2 venetoclax gemtuzumabozogamicin |
title | Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents |
title_full | Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents |
title_fullStr | Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents |
title_full_unstemmed | Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents |
title_short | Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents |
title_sort | refining aml treatment the role of genetics in response and resistance evaluation to new agents |
topic | AML mutations FLT3 IDH1/2 venetoclax gemtuzumabozogamicin |
url | https://www.mdpi.com/2072-6694/14/7/1689 |
work_keys_str_mv | AT adrianehalik refiningamltreatmenttheroleofgeneticsinresponseandresistanceevaluationtonewagents AT christophermaximilianarends refiningamltreatmenttheroleofgeneticsinresponseandresistanceevaluationtonewagents AT larsbullinger refiningamltreatmenttheroleofgeneticsinresponseandresistanceevaluationtonewagents AT frederikdamm refiningamltreatmenttheroleofgeneticsinresponseandresistanceevaluationtonewagents AT mareikefrick refiningamltreatmenttheroleofgeneticsinresponseandresistanceevaluationtonewagents |